Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Oncology Data Advisor
R

Phase 1/2 EPCORE NHL-2 Trial: Investigating Epcoritamab for R/R Follicular Lymphoma & Beyond

By Oncology Data Advisor FEATURING Reid Merryman
By Oncology Data Advisor FEATURING Reid Merryman
51 views
September 11, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
Lymphoma
12:43
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Bispecific Antibodies or CAR T-Cells for Indolent B-NHL?

Feat. C. Jacobson
05:36
Oncology Data Advisor

Phase 1/2 EPCORE NHL-2 Trial: Investigating Epcoritamab for R/R Foll…

Feat. R. Merryman
10:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Epcoritamab + R² Regimen and Responses in…

Feat. R. Merryman
19:42
Indy Hematology Review

Beyond Hyperviscosity: 80 Years and Counting - Treatment of Waldenst…

Feat. S. Treon
12:50
ASH 2022 Conference Coverage

ASH 2022 on Ibrutinib and Venetoclax in Previously Untreated Waldens…

Feat. J. Castillo
13:46
Dana-Farber Cancer Institute

Venetoclax in Previously Treated Waldenström Macroglobulinemia

Feat. J. Castillo